Hospital
Mary Rutan Hospital
Mary Rutan Hospital was paid $15.79M by Medicaid between Jan 2018 and Dec 2024, across 236 billing codes. Its largest line is 99284, emergency room visit (serious) — 11% of everything it billed.
33Billing provider infoMARY RUTAN HOSPITAL
BELLEFONTAINE, OH 43311
BELLEFONTAINE, OH 43311
33aNPI1548254931assigned 08/31/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.79M
24GClaims403,691
24DCodes billed236
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Ohio
Rank by total paid#59 of 101
Median peer was paid$22.32M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 46,557 | $1.86M | |
| 2019 | 48,749 | $1.91M | |
| 2020 | 23,255 | $954K | |
| 2021 | 31,026 | $1.22M | |
| 2022 | 41,541 | $1.71M | |
| 2023 | 126,356 | $4.68M | |
| 2024incomplete | 86,207 | $3.46M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 16,334 | 14,544 | $1.72M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 10% | 35,390 | 26,714 | $1.62M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.1% | 13,018 | 11,947 | $1.44M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 7.0% | 16,690 | 4,441 | $1.11M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 7.0% | 9,830 | 9,017 | $1.10M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 6.8% | 16,084 | 3,752 | $1.07M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 6.8% | 18,541 | 16,584 | $1.07M |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.9% | 3,508 | 2,566 | $932K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2.6% | 6,593 | 2,130 | $410K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 2.5% | 6,930 | 2,157 | $399K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 1,624 | 1,407 | $385K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.1% | 2,920 | 2,571 | $333K |
224 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 1,350 | $296K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.6% | 5,376 | $260K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 1,013 | $259K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 1.3% | 3,516 | $199K |
| 59025 | Fetal non-stress test | 1.2% | 1,288 | $184K |
| 80053 | Comprehensive metabolic panel | 1.0% | 21,775 | $161K |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.0% | 1,659 | $160K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 926 | $136K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,459 | $128K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 3,331 | $103K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,600 | $98K |
| 97161 | <1% | 1,361 | $94K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,062 | $91K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 522 | $89K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,710 | $87K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 694 | $83K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 378 | $81K |
| 92526 | <1% | 1,907 | $70K | |
| G0378 | Hospital observation service, per hour | <1% | 1,281 | $68K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,519 | $64K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,544 | $64K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,600 | $62K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 3,764 | $57K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 55 | $54K |
| 97016 | <1% | 1,414 | $52K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 2,174 | $49K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19,883 | $48K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 223 | $46K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 447 | $40K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 327 | $34K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,377 | $34K |
| 36415 | Collection of venous blood by venipuncture | <1% | 21,439 | $34K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,338 | $33K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,894 | $33K |
| 97162 | <1% | 455 | $32K | |
| 80061 | Lipid panel | <1% | 2,564 | $31K |
| 92557 | <1% | 366 | $29K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,504 | $29K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 572 | $29K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,432 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,284 | $26K |
| 87070 | <1% | 1,947 | $25K | |
| 99285 | Emergency room visit (most serious) | <1% | 175 | $24K |
| 74018 | <1% | 643 | $21K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 730 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,289 | $18K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,605 | $18K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 440 | $16K |
| 51798 | <1% | 377 | $16K | |
| 84439 | <1% | 1,591 | $14K | |
| 82728 | <1% | 819 | $14K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 663 | $14K |
| 92567 | <1% | 1,271 | $14K | |
| 86850 | <1% | 643 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,710 | $12K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 27 | $11K |
| 82607 | <1% | 771 | $11K | |
| 86592 | <1% | 337 | $10K | |
| 87077 | <1% | 976 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,199 | $10K |
| 86803 | <1% | 515 | $9K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,018 | $9K |
| 84484 | <1% | 6,299 | $9K | |
| 86900 | <1% | 729 | $8K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 91 | $8K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 572 | $8K |
| 73030 | <1% | 373 | $8K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 52 | $8K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 373 | $8K |
| 76536 | <1% | 71 | $7K | |
| 87653 | <1% | 222 | $7K | |
| 86787 | <1% | 300 | $7K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 119 | $7K |
| 73630 | <1% | 399 | $6K | |
| 76642 | <1% | 48 | $6K | |
| 87480 | <1% | 366 | $6K | |
| 84702 | <1% | 421 | $6K | |
| 83540 | <1% | 635 | $6K | |
| 92587 | <1% | 71 | $6K | |
| 97167 | <1% | 43 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 98 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,551 | $6K |
| 87186 | <1% | 948 | $5K | |
| 82746 | <1% | 578 | $5K | |
| 93017 | <1% | 67 | $5K | |
| 97166 | <1% | 127 | $5K | |
| 85007 | <1% | 3,075 | $5K | |
| 90686 | <1% | 829 | $5K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 43 | $5K |
| 83550 | <1% | 519 | $5K | |
| 81001 | <1% | 8,807 | $4K | |
| 86780 | <1% | 202 | $4K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 85 | $4K |
| 71250 | <1% | 92 | $4K | |
| 82950 | <1% | 362 | $4K | |
| 97750 | <1% | 99 | $4K | |
| 87634 | <1% | 93 | $4K | |
| 82570 | <1% | 562 | $4K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 17 | $4K |
| 92523 | <1% | 49 | $4K | |
| 83735 | <1% | 2,173 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 12 | $4K |
| 0352U | <1% | 151 | $3K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 573 | $3K |
| 87660 | <1% | 365 | $3K | |
| 85027 | <1% | 3,173 | $3K | |
| 90648 | <1% | 424 | $3K | |
| 87510 | <1% | 365 | $3K | |
| 72110 | <1% | 70 | $3K | |
| 86901 | <1% | 729 | $3K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 234 | $3K |
| 93971 | <1% | 43 | $3K | |
| 80081 | <1% | 134 | $3K | |
| 73610 | <1% | 212 | $3K | |
| 84703 | <1% | 3,239 | $3K | |
| 92555 | <1% | 77 | $3K | |
| 84153 | <1% | 159 | $2K | |
| 86038 | <1% | 91 | $2K | |
| 85610 | <1% | 1,209 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 28 | $2K |
| 90670 | <1% | 545 | $2K | |
| 87340 | <1% | 136 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 60 | $2K |
| 97113 | <1% | 38 | $2K | |
| 72131 | <1% | 18 | $2K | |
| 84403 | <1% | 122 | $2K | |
| 73560 | <1% | 91 | $2K | |
| 87205 | <1% | 386 | $2K | |
| 82565 | <1% | 236 | $2K | |
| 85652 | <1% | 428 | $2K | |
| 73130 | <1% | 180 | $2K | |
| 84550 | <1% | 379 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 38 | $2K |
| 73502 | <1% | 84 | $2K | |
| 72100 | <1% | 51 | $2K | |
| 83880 | <1% | 786 | $2K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,607 | $2K |
| 73110 | <1% | 92 | $1K | |
| 83001 | <1% | 73 | $1K | |
| 83690 | <1% | 3,438 | $1K | |
| 92610 | <1% | 28 | $1K | |
| 96376 | <1% | 802 | $1K | |
| 96367 | <1% | 70 | $1K | |
| 93289 | <1% | 79 | $1K | |
| 86140 | <1% | 150 | $1K | |
| 85730 | <1% | 1,477 | $1K | |
| 90723 | <1% | 283 | $1K | |
| 97802 | <1% | 12 | $1K | |
| 83525 | <1% | 52 | $1K | |
| 86762 | <1% | 97 | $1K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,041 | $943.31 |
| 82043 | <1% | 157 | $928.13 | |
| 84156 | <1% | 306 | $906.93 | |
| 81003 | <1% | 173 | $848.88 | |
| 73564 | <1% | 15 | $834.42 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,637 | $810.62 |
| 90680 | <1% | 191 | $792.92 | |
| 87806 | <1% | 32 | $736.64 | |
| 83605 | <1% | 1,235 | $734.42 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 138 | $724.19 |
| 69210 | <1% | 42 | $723.66 | |
| 97165 | <1% | 15 | $699.48 | |
| 85379 | <1% | 734 | $688.08 | |
| 80076 | <1% | 57 | $650.42 | |
| 90633 | <1% | 82 | $612.90 | |
| 86141 | <1% | 15 | $586.75 | |
| 80055 | <1% | 29 | $543.20 | |
| 70486 | <1% | 13 | $472.65 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 15 | $424.52 |
| 99201 | <1% | 18 | $378.45 | |
| 90715 | <1% | 27 | $377.34 | |
| 82803 | <1% | 639 | $352.86 | |
| 88304 | <1% | 64 | $292.84 | |
| 85018 | <1% | 60 | $280.19 | |
| 80143 | <1% | 246 | $279.44 | |
| 88342 | <1% | 19 | $262.08 | |
| 86430 | <1% | 20 | $248.86 | |
| 77066 | Tomosynthesis, mammo | <1% | 14 | $245.20 |
| 82550 | <1% | 178 | $244.94 | |
| 87640 | <1% | 12 | $201.63 | |
| 90647 | <1% | 28 | $173.31 | |
| 84145 | <1% | 629 | $166.22 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,222 | $161.62 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,051 | $161.54 |
| 84481 | <1% | 15 | $148.47 | |
| 84520 | <1% | 30 | $133.88 | |
| 87040 | <1% | 887 | $129.88 | |
| 82150 | <1% | 171 | $123.90 | |
| 90716 | <1% | 14 | $120.76 | |
| 87641 | <1% | 12 | $100.83 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,775 | $93.94 |
| J7121 | 5% dextrose in lactated ringers infusion, up to 1000 cc | <1% | 1,539 | $76.03 |
| 90707 | <1% | 14 | $63.01 | |
| 80179 | <1% | 223 | $62.42 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 877 | $57.89 |
| 90685 | <1% | 15 | $52.52 | |
| 82652 | <1% | 17 | $41.18 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,746 | $31.21 |
| 83615 | <1% | 17 | $29.91 | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 239 | $22.50 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 50 | $19.80 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 402 | $16.54 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 149 | $14.38 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,423 | $10.83 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,423 | $9.61 |
| 87807 | <1% | 13 | $7.76 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 260 | $5.58 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 23 | $3.40 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 247 | $2.13 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,266 | $1.85 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 42 | $1.06 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 37 | $1.04 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 18 | $0.40 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 871 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 12 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 52 | $0.00 |
| 94760 | 0% | 21 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 16 | $0.00 |
| 00126 | 0% | 13 | $0.00 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 229 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 27 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 20 | $0.00 |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 0% | 15 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROSS, CHAD (PRESIDENT/CEO)
| Provider | Location | Paid |
|---|---|---|
| Mary Rutan Hospital | Bellefontaine, OH | $3.88M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.